BioCentury
ARTICLE | Strategy

OSI Chronicles

March 8, 2010 8:00 AM UTC

Shares of OSI Pharmaceuticals Inc. jumped 139% to an all-time high of $91.10 in April 2004 when Tarceva erlotinib met the primary endpoint in a Phase III trial in non-small cell lung cancer (NSCLC). S...